Table 4.
Multi-group models by gender: Structural equation models of depressive symptoms, withdrawal-relevant negative affect, and craving.
| Variable | Path | Est | Bias-Corrected 95% CI | χ2 (df) | p-value | RMSEA (90% CI) | Prob. ≤ .05 | CFI | WRMR |
|---|---|---|---|---|---|---|---|---|---|
| Depressive Symptoms | |||||||||
| Female a | Pre-quit slope on fluoxetine (as) | −1.321 | (−2.707, −0.313)** | 8.12 (11) | 0.703 | 0.000 (0.000, 0.080) | 0.847 | 1.000 | 0.457 |
| TQD abst on pre-tx intercept (bi) | −0.050 | (−0.097, −0.015)** | |||||||
| TQD abst on pre-quit slope (bs) | −0.287 | (−0.933, −0.116)** | |||||||
| Male | Pre-quit slope on fluoxetine (as) | 0.095 | (−0.937, 1.035) | ||||||
| TQD abst on pre-tx intercept (bi) | −0.056 | (−0.122, 0.051) | |||||||
| TQD abst on pre-quit slope (bs) | −0.063 | (−0.695, 0.351) | |||||||
| Withdrawal-Relevant Negative Affect | |||||||||
| Female | Pre-quit slope on fluoxetine (as) | −0.116 | (−0.194, −0.039)** | 47.46 (41) | 0.226 | 0.039 (0.000, 0.081) | 0.620 | 0.962 | 0.887 |
| TQD abst on pre-tx intercept (bi) | −1.051 | (−3.628, 0.179) | |||||||
| TQD abst on pre-quit slope (bs) | 0.104 | (−0.155, 0.677) | |||||||
| Male | Pre-quit slope on fluoxetine (as) | −0.030 | (−0.098, 0.037) | ||||||
| TQD abst on pre-tx intercept (bi) | −0.666 | (−1.527, 0.580) | |||||||
| TQD abst on pre-quit slope (bs) | −4.101 | (−10.45, −0.273)* | |||||||
| Craving b | |||||||||
| Female | Pre-quit slope on fluoxetine (as) | −0.109 | (−0.181, −0.034)** | 39.18 (40) | 0.507 | 0.000 (0.000, 0.066) | 0.846 | 1.000 | 0.819 |
| TQD abst on pre-tx intercept (bi) | 0.141 | (−1.424, 3.140) | |||||||
| TQD abst on pre-quit slope (bs) | −7.883 | (−71.35, −2.396)** | |||||||
| Male | Pre-quit slope on fluoxetine (as) | −0.013 | (−0.077, 0.054) | ||||||
| TQD abst on pre-tx intercept (bi) | 1.619 | (0.161, 6.523)** | |||||||
| TQD abst on pre-quit slope (bs) | −2.306 | (−11.97, 1.231) | |||||||
P < 0.05,
P < 0.00.
TQD: target quit date; pre-tx: pre-treatment; FTND: Fagerström Test for Nicotine Dependence; Est: estimate; SE: standard error; CI: confidence interval; stdXY: fully standardized; RMSEA: root mean square error of approximation; CFI: Comparative Fit Index; WRMR: weighted root mean square residual.
Note: For parsimony, paths c′ (i.e., TQD abstinence on fluoxetine - all non-significant) and nicotine dependence (i.e., pre-tx intercepts on FTND & TQD abstinence on FTND) are not presented in the table.
The intercept and slope were significantly correlated only in the female model of depressive symptoms.
The association between baseline nicotine dependence levels and pre-quit intercept was modeled in each model (not presented in the table). Baseline nicotine dependence was significantly associated only with pre-quit intercept of craving (in both the female and male models).